Mesenchymal stem cells: A future experimental exploration for recession of diabetic nephropathy

Renal Failure

Volumn 39, Issue 1, 2017, Pages 67-76

  Hamza, Amal H ^a,b   Al Bishri, Widad M ^a   Damiati, Laila A ^c   Ahmed, Hanaa H ^d  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b Ain Shams University   (Egypt)

^c UNIVERSITY OF JEDDAH   (Saudi Arabia)

^d NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Diabetes; Diabetic nephropathy; Growth factors; Inflammatory mediators; Oxidative stress markers; Stem cells

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; CREATININE; FIBROBLAST GROWTH FACTOR 2; GLUCOSE; HEME OXYGENASE 1; INSULIN; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; UREA; URIC ACID; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ADULT; AGAR GEL ELECTROPHORESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMICAL ANALYSIS; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CONTROLLED STUDY; EXPERIMENTAL DIABETES MELLITUS; EXPERIMENTAL DIABETIC NEPHROPATHY; FEMALE; FLOW CYTOMETRY; GENETIC ANALYSIS; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; INSULIN BLOOD LEVEL; KIDNEY FUNCTION; KIDNEY STRUCTURE; KIDNEY TISSUE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PANCREAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; ANALYSIS; ANIMAL; BLOOD; COMPLICATION; DIABETIC NEPHROPATHIES; DISEASE MODEL; KIDNEY; MALE; MESENCHYMAL STROMA CELL; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; GLYCOSYLATION END PRODUCTS, ADVANCED; HEME OXYGENASE-1; INSULIN; KIDNEY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; PANCREAS; RATS; TREATMENT OUTCOME;

EID: 85027951583     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/0886022X.2016.1244080     Document Type: Article

References (49)

1. Abu-Rmeileh NM, Husseini A, Capewell S, O’Flaherty M. Preventing type 2 diabetes among Palestinians: Comparing five future policy scenarios. BMJ Open. 2013;3:e003558.
2. Xi Y, Bu S. Stem cells therapy in diabetes mellitus. J Stem Cell Res Ther. 2014;4:5. http://dx.doi.org/10.4172/2157-7633.1000199.
3. Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest. 2001;108:261-268.
4. Wang G, Lu X, Li W, Zhao X, Zhang C. Protective effects of luteolin on diabetic nephropathyin STZ-induced diabetic rats. Evid Based Complement Alternat Med. 2011;2011:7.
5. Abdel Aziz MT, Wassef MA, et al. The role of bone marrow derived-mesenchymal stem cells in attenuation of kidney function in rats with diabetic nephropathy. Diabetol Metab Syndr. 2014;6:34.
6. Forbes JM, Fukami K, Cooper ME. Diabetic nephropathy: Where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes. 2007;115:69-84.
7. Weissman IL. Stem cells: Units of development, units of regeneration, and units in evolution. Cell. 2000;100:157-168.
8. Porada CD, Zanjani ED, Almeida-Porad G. Adult mesenchymal stem cells: A pluripotent population with multiple applications. Curr Stem Cell Res Ther. 2006;1:365-369.
9. Volarevic V, Arsnijevic N, Lukic M, Stojkovic M. Concise review: Mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem Cells. 2011;29:5-10.
10. Weir G, Weder C, Weir SB. Stem cell approaches for diabetes: Towards beta cell replacement. Genome Med. 2011;3:61. http://genomemedicine.com/content/3/9/61.
11. Woodbury D, Schwarz EJ, Prockop DJ, Black IB. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res. 2000; 61:364-370.
12. Balakumar P, Chakkarwar VA, Kumar V, Jain A, Reddy J, Singh M. Experimental models for nephropathy. J Renin Angiotensin Aldosterone Syst. 2008; 9:4.
13. Larsen K. Creatinine assay by a reaction-kinetic principle. Clin Chim Acta. 1972;41:209-217.
14. Orsonneau JL, Massoubre C, Cabanes M. Lustenberger Simple and sensitive determination of urea in serum and urine. Clin Chem. 1992; 38:619-623.
15. Buchanan MJ, Isdale IC, Rose BS. Serum uric acid estimation chemical and enzymatic methods compared. Ann Rheum Dis. 1965;24:285-288.
16. Gornall AG, Bardawill CJ, David M. Determination of serum proteins by means of the biuret reaction. J Biol Chem. 1949;177:201-207.
17. Doumas BT, Watson WA, Biggs HG. Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta. 1971;31:87-96.
18. Soliman MM, Nassan MA, Ismail TA. Immunohistochemical and molecular study on the protective effect of curcumin against hepatictoxicity induced by paracetamol in Wistar rats. BMC Complement Altern Med. 2014;14:112.
19. Paul S, Kundu R. Antiproliferative activity of methanolic extracts from two green algae, Enteromorpha intestinalis and Rizoclonium riparium on HeLa cells. DARU J Pharm Sci. 2013;21:1-12.
20. Hajiasgharzadeh K, Tavangar SM, Javan M, Dehpour AR, Mani AR. Does hepatic vagus nerve modulate the progression of biliary fibrosis in rats? Auton Neurosci. 2014;185:67-75.
21. Banchroft JD, Stevens A, Turner DR. Theory and Practice of Histological Techniques. 4th ed. New York, London, San Francisco, Tokyo: Churchill Livingstone; 1996.
22. Abramoff M. Image processing with imageJ. Biophotonics International. Imaging Software. 2004;11:36-42.
23. Kim JJ, Kido Y, Scherer PE, White MF, Accili D. Analysis of compensatory beta-cell response in mice with combined mutations of Insr and Irs2. Am J Physiol Endocrinol Metab. 2007;292:E1694-E1701.
24. Weir GC, Marselli L, Marchetti P, Katsuta H, Jung MH, Bonner-Weir S. Towards better understanding of the contributions of overwork and glucotoxicity to the beta-cell inadequacy of type 2 diabetes. Diabetes Obes Metab. 2009;11(Suppl 4):82-90.
25. Satchell S, Tooke J. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia. 2008;51:714-725.
26. Gomes KB, Rodrigues KF, Fernandes AP. The role of transforming growth factor-beta in diabetic nephropathy. Int J Med Genetics. 2014;2014:6. http://dx.doi.org/10.1155/2014/180270.
27. Feig DI, Kang D, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811-1821.
28. Amartey AA, Nsiah K, Mensa FO. Plasma levels of uric acid, urea and creatinine in diabetics who visit the clinical analysis laboratory (CAn-Lab) at Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. J Clin Diagn Res. 2015;9:BC05-BC09.
29. Stitt AW, Li YM, Gardiner TA, Bucala R, Archar DB, Vlassara H. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol. 1997;150:523-531.
30. Kass DA, Shapiro EP, Kawaguchi M, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation. 2001;104:1464-1470.
31. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation. 2006;114:597-605.
32. Pitlovanciv E, Fernandes GS, Teixeira LC, et al. Hemeoxygenase 1 improves glucose metabolism and kidney histological alteration in diabetic rats. Diabetol Metab Syndr. 2013;5:3.
33. Elmarakby AA, Faulkner J, Baban B, Saleh MA, Sullivan JC. Induction of hemeoxygenase-1 reduces glomerular injury and apoptosis in diabetic spontaneously hypertensive rats. Am J Physiol Renal Physiol. 2012; 302:F791-F800.
34. Yener S, Comlekci A, Akinci B, et al. Serum transforming growth factor-beta 1 levels innormoalbuminuric and normotensive patients with type 2 diabetes. Effect of metformin and rosiglitazone. Hormones. 2008; 7:70-76.
35. Yener S, Demir T, Akinci B, et al. Transforming growth factor-beta 1 levels in women with prior history of gestational diabetes mellitus. Diabetes Res Clin Pract. 2007;76:193-198.
36. Langham RG, Kelly DJ, Maguire J, Dowling JP, Gilbert RE, Thomson NM. Over-expression of platelet-derived growth factor in human diabetic nephropathy. Nephrol Dial Transplant. 2003;18:1392-1396.
37. Vasko R, Koziolek M, Ikehata M, et al. Role of basic fibroblast growth factor (FGF-2) in diabetic nephropathy and mechanisms of its induction by hyperglycemia in human renal fibroblasts. Am J Physiol Renal Physiol. 2009;296:F1452-F1463.
38. Strutz F, Zeisberg M, Ziyadeh FN, et al. Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int. 2002;61:1714-1728.
39. Aydin M, Ozkok E, Ozturk O, et al. Relationship between interleukin-8 and the oxidant-antioxidant system in end-stage renal failure patients. Exp Clin Transplant. 2007;5:610-613.
40. Khajehdehi P, Pakfetrat M, Javidnia K, et al. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: A randomized, double-blind and placebo-controlled study. Scand J Urol Nephrol. 2011;45:365-370.
41. Jeon HJ, Choi HJ, Park BH, Lee YH, Oh T. Association of monocyte chemoattractant protein-1 (MCP-1) 2518A/G polymorphism with proliferative diabetic retinopathy in Korean type 2 diabetes. Yonsei Med J. 2013;54:621-625.
42. Chiarelli F, Cipollone F, Mohn A. Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes. Diabetes Care. 2002;25:1829-1834.
43. Morii T, Fujita H, Narita T, et al. Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J Diabetes Complications. 2003;17:11-15.
44. Antonello P. Mesenchymal stem cells for the treatment of diabetes. Diabetes. 2012;61:1355-1356
45. Anglani F, Forino M, Prete DD, Tosetto E, Torregrossa R, Angelo AD. In search of adult renal stem cells. J Cell Mol Med. 2004;8:474-487.
46. Wang S, Li Y, Zhao J, Zhang J, Huang Y. Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model. Biol Blood Marrow Transplant. 2013;19:538-546.
47. Rookmaaker MB, Verhaar MC, de Boer H, et al. Met-RANTES reduces endothelial progenitor cell homin to activated (glomular) endothelium in vitro and in vivo. Am J Physiol Renal Hysiol. 2007;293:F624-F630.
48. Duffield JS, Bonvenetre JV. Kidney tubular epithelium is restored without replacement with bone marrow-derived cells during repair after ischemic injury. Kidney Int. 2005;68:1956-1961.
49. Sha-Sha L, Liu G, Wang J, et al. Mesenchymal stem cells transplantation ameliorates glomerular injury in streptozotocin-induced diabetic nephropathy in rats via inhibiting macrophage infiltration. Int Immunopharmacol. 2013;17:275-282.